首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | GDF5 |
| Uniprot No | P43026 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 382-501aa |
| 氨基酸序列 | MAPLATRQGK RPSKNLKARC SRKALHVNFK DMGWDDWIIA PLEYEAFHCE GLCEFPLRSH LEPTNHAVIQ TLMNSMDPES TPPTCCVPTR LSPISILFIDSA NNVVYKQY EDMVVESCGC R |
| 预测分子量 | 55 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于GDF5重组蛋白的文献概览：
---
1. **文献名称**：*Recombinant human growth differentiation factor 5 (rhGDF5) induces bone formation in vivo*
**作者**：Hotten et al.
**摘要**：研究证明重组人GDF5蛋白在大鼠模型中显著促进骨形成，通过激活BMP信号通路增强成骨细胞分化，为骨折修复提供潜在治疗策略。
---
2. **文献名称**：*GDF5 enhances extracellular matrix synthesis in chondrocytes: Implications for cartilage regeneration*
**作者**：Coleman et al.
**摘要**：体外实验显示，重组GDF5通过上调胶原蛋白II和蛋白聚糖表达，促进软骨细胞外基质合成，支持其在关节软骨修复中的应用潜力。
---
3. **文献名称**：*Recombinant GDF5 synergizes with adipose-derived stem cells to accelerate tendon healing*
**作者**：Wang et al.
**摘要**：该研究结合重组GDF5与脂肪干细胞治疗大鼠肌腱损伤，发现两者协同作用显著提高肌腱力学性能和胶原纤维排列，优于单一治疗组。
---
如需更多文献，可进一步限定研究领域(如神经再生、临床转化等)。
**Background of GDF5 Recombinant Protein**
Growth Differentiation Factor 5 (GDF5), a member of the transforming growth factor-beta (TGF-β) superfamily, plays a critical role in skeletal development, joint formation, and tissue repair. Initially identified for its involvement in chondrogenesis and bone morphogenesis, GDF5 regulates cell differentiation, proliferation, and extracellular matrix synthesis. It signals through BMP (bone morphogenetic protein) receptors, activating SMAD-dependent pathways to influence cartilage and bone homeostasis.
GDF5 is synthesized as a precursor protein, processed into a mature, bioactive dimer through proteolytic cleavage. Recombinant GDF5 is produced using biotechnological systems (e.g., *E. coli*, mammalian cells) to mimic the native protein's structure and function. Its therapeutic potential is widely explored, particularly in treating degenerative joint diseases like osteoarthritis, where it promotes cartilage repair and mitigates inflammation.
Clinically, GDF5 mutations are linked to skeletal disorders such as brachydactyly and osteoarthritis susceptibility, highlighting its biological significance. In regenerative medicine, recombinant GDF5 is investigated for enhancing tendon/ligament healing, spinal fusion, and stem cell-based tissue engineering. Challenges include optimizing delivery systems to ensure localized, sustained activity and minimizing off-target effects (e.g., ectopic bone formation).
Current research focuses on engineering GDF5 variants with improved stability and bioavailability, as well as combinatorial therapies with biomaterials or other growth factors. Its dual role in both anabolic and anti-catabolic processes positions it as a promising candidate for addressing unmet needs in musculoskeletal and neurological disorders.
×
